Perspective Therapeutics (CATX) Depreciation and Depletion (2014 - 2024)
Perspective Therapeutics (CATX) reported Depreciation and Depletion of -$1.6 million for Q4 2024, down 250.66% on a YoY basis from $1.1 million in Q1 2024, and down 336.92% sequentially from $669000.0 in Q3 2024.
Perspective Therapeutics (CATX) Depreciation and Depletion (2014 - 2024) Analysis & Trends
Perspective Therapeutics (CATX) has 11 years of Depreciation and Depletion data on file, last reported at -$1.6 million in Q4 2024.
- For the quarter ending Q4 2024, Depreciation and Depletion fell 250.66% year-over-year to -$1.6 million; the trailing twelve-month figure through Sep 2025 stood at -$1.6 million (down 239.89% YoY), and the FY2023 full-year result was $232000.0, down 13.11% from the prior year.
- Depreciation and Depletion fell to -$1.6 million in Q4 2024, from $669000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $669000.0 in Q3 2024 to a low of -$1.6 million in Q4 2024.
- A 5-year average of $48315.8 and a median of $64000.0 in 2022 frame the typical range for Depreciation and Depletion.
- Across the five-year window, Depreciation and Depletion soared 276.92% in 2022 and tumbled 427.54% in 2023, its largest moves.
- Tracing CATX's Depreciation and Depletion over 5 years: stood at $37000.0 in 2020, then plunged by 310.81% to -$78000.0 in 2021, then soared by 276.92% to $138000.0 in 2022, then plunged by 427.54% to -$452000.0 in 2023, then slumped by 250.66% to -$1.6 million in 2024.
- Business Quant data shows CATX's Depreciation and Depletion at -$1.6 million in Q4 2024, $669000.0 in Q3 2024, and $570000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 381.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 120.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 308.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 89.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 78.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.59 Mn |
| Dec 31, 2024 | -1.59 Mn |
| Sep 30, 2024 | 669,000.00 |
| Sep 30, 2024 | 669,000.00 |
| Jun 30, 2024 | 570,000.00 |
| Jun 30, 2024 | 570,000.00 |
| Mar 31, 2024 | 346,000.00 |
| Mar 31, 2024 | 346,000.00 |
| Dec 31, 2023 | -452,000.00 |
| Dec 31, 2023 | -452,000.00 |
| Sep 30, 2023 | 259,000.00 |
| Sep 30, 2023 | 259,000.00 |
| Jun 30, 2023 | 245,000.00 |
| Jun 30, 2023 | 245,000.00 |
| Mar 31, 2023 | 180,000.00 |
| Mar 31, 2023 | 180,000.00 |
| Dec 31, 2022 | 138,000.00 |
| Dec 31, 2022 | 138,000.00 |
| Sep 30, 2022 | 197,000.00 |
| Sep 30, 2022 | 197,000.00 |